Cardlytics (NASDAQ:CDLX) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Cardlytics (NASDAQ:CDLX) from a hold rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

Several other analysts have also recently weighed in on CDLX. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a research note on Thursday, June 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cardlytics in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Sell” and an average target price of $10.00.

Cardlytics Price Performance

Shares of NASDAQ CDLX opened at $3.68 on Friday. The stock’s fifty day moving average price is $3.97 and its two-hundred day moving average price is $6.14. Cardlytics has a one year low of $3.49 and a one year high of $29.70. The firm has a market cap of $21.38 million, a price-to-earnings ratio of -0.20 and a beta of 0.67.

Cardlytics (NASDAQ:CDLX) last posted its earnings results on Wednesday, August 5th. The company reported ($1.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.30) by $0.80. The company had revenue of $36.88 million during the quarter, compared to the consensus estimate of $37.00 million. Cardlytics had a negative return on equity of 956.56% and a negative net margin of 55.92%. On average, equities analysts anticipate that Cardlytics will post -3.89 earnings per share for the current fiscal year.

Insider Buying and Selling at Cardlytics

In related news, CEO Amit Gupta sold 6,676 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $4.03, for a total transaction of $26,904.28. Following the sale, the chief executive officer owned 125,389 shares in the company, valued at approximately $505,317.67. This trade represents a 5.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have sold 31,750 shares of company stock worth $134,129. Corporate insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Cardlytics

A hedge fund recently bought a new position in Cardlytics stock. Worldly Partners Management LLC acquired a new stake in shares of Cardlytics, Inc. (NASDAQ:CDLX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 115,798 shares of the company’s stock, valued at approximately $520,000. Cardlytics accounts for approximately 0.4% of Worldly Partners Management LLC’s investment portfolio, making the stock its 3rd largest holding. Worldly Partners Management LLC owned 1.99% of Cardlytics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 68.10% of the company’s stock.

About Cardlytics

Cardlytics, Inc is an advertising technology company that connects marketers with consumers through financial institutions. Its platform uses transaction-based insights to help advertisers reach customers with relevant offers and measure the impact of advertising on consumer spending.

Cardlytics’ services are integrated into banking and financial applications, where consumers may receive personalized cash-back offers, discounts and other promotions based on their shopping activity. Participating financial institutions can use the platform to provide additional value to customers while generating advertising revenue.

The company serves advertisers across categories such as retail, dining, travel and financial services, and works with banks and other financial institutions primarily in the United States and the United Kingdom.